Bempedoic Acid is Your Best Option
For a patient who has experienced adverse reactions to Repatha (alirocumab), ezetimibe, and statins, bempedoic acid is the recommended lipid-lowering therapy. This agent provides proven cardiovascular benefit with a distinct mechanism of action and safety profile that does not overlap with the medications you've already tried 1.
Why Bempedoic Acid Works Here
Bempedoic acid is a liver-selective ATP citrate lyase inhibitor that lowers LDL-C by 21-24% as monotherapy 1. Critically, the CLEAR Outcomes trial demonstrated a statistically significant reduction in major adverse cardiovascular events in patients with statin intolerance, with a number-needed-to-treat of 43 for high-risk primary prevention 1. This is the only non-statin agent besides PCSK9 inhibitors with proven cardiovascular outcomes data.
The drug's mechanism is entirely distinct from:
- Statins (which you cannot tolerate)
- Ezetimibe (which caused adverse reactions)
- PCSK9 inhibitors like Repatha (which you've already reacted to)
Important Safety Considerations
Watch for two specific adverse effects with bempedoic acid:
- Gout flares: The drug increases uric acid levels slightly 2, 3
- Tendon rupture risk: Use caution if you have a history of tendon problems 2
If you have a history of gout or tendon disorders, these need to be weighed carefully, but bempedoic acid should still be considered given your limited options.
Alternative PCSK9 Inhibitor Option
Since you reacted to Repatha (alirocumab), you might still tolerate evolocumab, the other PCSK9 monoclonal antibody 1. These are different molecules with potentially different side effect profiles. The 2026 ACC/AHA guidelines note that PCSK9 mAbs demonstrated efficacy and safety in the GAUSS-3 trial specifically for statin-intolerant patients, with evolocumab showing better tolerability than statins 1.
If you cannot tolerate evolocumab either, inclisiran becomes reasonable 1. This is a small interfering RNA-based PCSK9 inhibitor given twice yearly, with a 48-52% LDL-C reduction and excellent tolerability 1. While cardiovascular outcomes data are still pending (ORION-4 trial expected 2026), pooled analysis showed 45.8% LDL-C reduction with good safety 1.
Sequencing Strategy
Here's the algorithmic approach:
Start bempedoic acid (unless contraindicated by gout/tendon history)
- Expect ~21-24% LDL-C reduction
- Monitor uric acid levels
- Assess LDL-C response at 8-12 weeks
If LDL-C goals not met on bempedoic acid alone:
- Consider trial of evolocumab (different from Repatha/alirocumab)
- If evolocumab not tolerated, try inclisiran
- These can be added to bempedoic acid for additive effect
If all injectable PCSK9 inhibitors fail:
- Continue bempedoic acid as monotherapy
- Intensify lifestyle modifications
- Consider referral to lipid specialist 2
What About Re-trying Ezetimibe?
The guidelines suggest that some patients may have nocebo effects or symptoms unrelated to the actual medication 1. However, given your documented adverse reaction to ezetimibe, bempedoic acid remains the safer first choice rather than re-challenging with ezetimibe.
Critical Pitfall to Avoid
Do not assume all PCSK9 inhibitors will cause the same reaction. Alirocumab (Repatha), evolocumab, and inclisiran are mechanistically similar but structurally different molecules. Your reaction to alirocumab does not guarantee reactions to the others 1. The most common adverse effect of PCSK9 mAbs is injection site reactions (usually mild), which differs from systemic adverse effects 4, 3.
Emerging Options (Not Yet Recommended)
While evinacumab (ANGPTL3 inhibitor) and CETP inhibitors are emerging 5, 6, these lack cardiovascular outcomes data and are not currently recommended for routine use outside of homozygous familial hypercholesterolemia for evinacumab 2.